Abcellera Biologics Stock Pattern Recognition Short Line Candle
| ABCL Stock | USD 3.57 0.05 1.42% |
| Symbol |
Recognition |
The output start index for this execution was ten with a total number of output elements of fifty-one. The function generated a total of four valid pattern recognition events for the selected time horizon. The Short Line Candle pattern describes signals for either bullish or bearish trend during either reversal or continuation condition of Abcellera Biologics.
Abcellera Biologics Technical Analysis Modules
Most technical analysis of Abcellera Biologics help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Abcellera from various momentum indicators to cycle indicators. When you analyze Abcellera charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Abcellera Biologics Inc
AbCellera Biologics Inc. develops antibody discovery platform. The company was incorporated in 2012 and is headquartered in Vancouver, Canada. Abcellera Biologics is traded on NASDAQ Exchange in the United States. A high-level view of Abcellera Biologics emphasizes earnings durability, balance-sheet flexibility, and competitive positioning. Current metrics include P/E of 16.67, P/B of 1.12, profit margin of -1.95%. Abcellera Biologics has a market cap of 1.08 B, P/E of 16.67, ROE of -14.48%. 
Gabriel Shpitalnik · Member of Macroaxis Editorial Board
Methodology
Unless otherwise specified, financial data for Abcellera Biologics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Abcellera (USA Stocks:ABCL) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Macroaxis analytics incorporate public filings and market reference sources and official disclosures from U.S. Securities and Exchange Commission (SEC) via EDGAR. Data harmonization may result in minor timing offsets. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Abcellera Biologics may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Abcellera Stock is Curated By:
Gabriel Shpitalnik · Member of Macroaxis Editorial BoardSome investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Abcellera Biologics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Abcellera Biologics' short interest history, or implied volatility extrapolated from Abcellera Biologics options trading.
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | FinTech Invested over 20 shares | |
 | Hedge Favorites Invested over 40 shares | |
 | Investor Favorites Invested over 60 shares | |
 | Impulse Invested over 200 shares | |
 | Adviser Favorites Invested few shares | |
 | Macroaxis Index Invested over 60 shares | |
 | Artificial Intelligence Invested few shares | |
 | Momentum Invested over 20 shares | |
 | Marketing Invested few shares | |
 | Driverless Cars Invested over 200 shares |
More Resources for Abcellera Stock Analysis
A structured review of Abcellera Biologics often starts with core financial statements and trend context. Financial ratios provide context for profitability, efficiency, and growth trends. Below are reports that help frame Abcellera Biologics Stock in context:Abcellera Biologics has a market cap of 1.08 B, operating margin of -63.72%, ROE of -14.48%. Use Trending Equities to explore allocation context. This includes a position in Abcellera Biologics across the allocation. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services.For more information on how to buy Abcellera Stock please use our How to Buy Abcellera Stock guide.Analysis related to Abcellera Biologics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
The market value of Abcellera Biologics is measured differently than book value, which reflects Abcellera accounting equity. Abcellera Biologics' market capitalization is 1.08 B. A P/B ratio of 1.12 indicates the market values Abcellera Biologics above its accounting book value. Enterprise value stands at 694.71 M. The intrinsic value concept focuses on underlying worth, which can diverge from market price and book value. Valuation work aligns these measures into a single context.
Note that Abcellera Biologics' intrinsic value and market price are different measures derived from different inputs. For Abcellera Biologics, key inputs include a P/E ratio of 16.67, a P/B ratio of 1.12, a profit margin of -1.95%, and ROE of -14.48%. Trading price represents the transaction level agreed by market participants.